In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

The Capecitabine market is experiencing growth due to increasing demand for effective chemotherapy treatments, particularly in colorectal and breast cancer. Key factors driving the market include ...

Background. A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin.

Capecitabine (Xeloda) is a type of oral chemotherapy often prescribed to treat metastatic breast cancer. It’s sometimes used alongside targeted therapy, or on its own if the cancer has stopped ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

Herrmann et al. compared the safety and efficacy of gemcitabine plus capecitabine (GemCap) with that of gemcitabine monotherapy in patients with pancreatic cancer. This phase III trial included ...

Besides carboplatin and cisplatin, other cancer drugs with limited availability include 5-fluorouracil, fludarabine phosphate, dacarbazine, methotrexate, amifostine, azacitidine, and capecitabine.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

The COVID-19 pandemic has enabled researchers to show that a long course of radiotherapy given before surgery may be a better ...

Often given as combination of drugs. 5-Fluorouracil. Capecitabine. Oxaliplatin Targeted therapy: Kills specifically cancer ...

Market research from the manufacturers of capecitabine indicates that the clinical community has voted with its empirical feet—it is relatively rare for US-based oncologists to prescribe the ...

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape. The most common ...